Details

Last Funding Type

Debt Financing

Last Funding Money Raised

€1.40M

Industries

Biotechnology,Health Care,Medical,Pharmaceutical

Founded date

Jan 1, 2021

Operating Status

Active

Also Known As

Agalaia Therapeutics

Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.